F/m Emerald Life Sciences Innovation ETF Rating $38.31 0.00 (0.00%) As of 05/22/2026 01:30 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock F/m Emerald Life Sciences Innovation ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LFSC Aggregate RatingModerate Buy 2.81Holdings in LFSC have an aggregate rating of Moderate Buy based on 306 analyst ratings issued in the past year covering 24 companies (85.1% of the portfolio).LFSC Aggregate Price Target$38.31High Prediction$38.31Average Prediction$38.31Low Prediction$38.31Holdings in LFSC have an aggregate price target of $38.31 and a range of $38.31 to $38.31 covering 24 companies (85.1% of the portfolio).LFSC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold1 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by F/m Emerald Life Sciences Innovation ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 24 LFSC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.49%TVTXTravere Therapeutics$44.431.5446 of 5 stars2.69$47.83 7.7%137.48%LIVNLivaNova$73.832.1969 of 5 stars2.67$79.38 7.5%97.26%COGTCogent Biosciences$32.672.3054 of 5 stars2.86$43.73 33.8%146.57%SYRESpyre Therapeutics$74.052.5833 of 5 stars3.00$90.25 21.9%134.98%MIRMMirum Pharmaceuticals$98.623.2811 of 5 stars2.93$137.08 39.0%15Analyst DowngradeGap Up4.55%UTHRUnited Therapeutics$568.433.9188 of 5 stars2.85$619.42 9.0%134.38%GHGuardant Health$118.952.0331 of 5 stars2.86$129.00 8.4%21Insider Trade3.65%MANEMANE$101.42-0.2%N/A2.80$100.00 -1.4%5Gap Up3.56%NKTRNektar Therapeutics$66.612.9898 of 5 stars2.73$149.63 124.6%11Gap Up3.43%BBIOBridgeBio Pharma$69.123.5122 of 5 stars2.88$88.90 28.6%25Gap Up3.27%SVRASavara$5.022.3314 of 5 stars2.78$9.13 81.8%93.18%TRVITrevi Therapeutics$14.133.0068 of 5 stars3.00$22.90 62.1%122.98%DNTHDianthus Therapeutics$86.482.2197 of 5 stars3.00$117.82 36.2%14Gap Up2.96%AXSMAxsome Therapeutics$235.972.6009 of 5 stars2.90$251.26 6.5%212.46%TMDXTransMedics Group$68.934.4102 of 5 stars2.50$135.00 95.9%122.28%CYTKCytokinetics$76.942.9512 of 5 stars2.86$99.30 29.1%22Positive News2.20%VRDNViridian Therapeutics$17.243.157 of 5 stars2.79$36.14 109.6%14Gap Up2.07%CRVSCorvus Pharmaceuticals$12.612.3546 of 5 stars2.71$33.33 164.3%72.04%ICUIICU Medical$133.313.8327 of 5 stars3.00$169.00 26.8%51.91%CORTCorcept Therapeutics$60.223.8462 of 5 stars2.75$70.83 17.6%8Analyst Revision1.86%PVLAPalvella Therapeutics$113.993.4789 of 5 stars2.94$199.53 75.0%161.53%ITGRInteger$89.34+0.1%2.3995 of 5 stars2.27$98.29 10.0%11Analyst Revision1.50%CBLLCeriBell$18.771.9439 of 5 stars2.83$22.20 18.3%6Positive News1.49%BLLNBilliontoone$85.923.276 of 5 stars2.50$125.29 45.8%10 This page (NASDAQ:LFSC) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F/m Emerald Life Sciences Innovation ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share F/m Emerald Life Sciences Innovation ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
